Cardiol Therapeutics | WebDisclosure

Basculer en Français

8205	Companies
109437	Keywords
51603	Articles
60273	Press releases

Home
Companies
Cardiol Therapeutics

BRIEF

published on 10/28/2024 at 15:51, 7 days 13 hours ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
BRIEF

published on 10/28/2024 at 15:51, 7 days 13 hours ago

Cardiol Therapeutics lance un essai clinique de phase II/III pour la péricardite récurrente

Essai Clinique CardiolRx Péricardite Récurrente Thérapeutique Cardiol Essai MAVERIC-2
PRESS RELEASE

published on 10/28/2024 at 15:46, 7 days 13 hours ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 4 months 20 days ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
BRIEF

published on 06/14/2024 at 14:57, 4 months 20 days ago

Cardiol Therapeutics Inc reçoit une note « d'achat » mise à jour de la part de First Berlin Equity Research

Acheter Une Note CardiolRx Cardiol Thérapeutique Péricardite Récurrente Étude De Phase II
PRESS RELEASE

published on 06/14/2024 at 14:52, 4 months 20 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx
BRIEF

published on 02/27/2024 at 14:16, 8 months 6 days ago

Cardiol Therapeutics obtient la désignation de médicament orphelin par la FDA pour CardiolRx

Investissement FDA Orphan Drug Designation Cardiol Therapeutics Pericardite
BRIEF

published on 02/27/2024 at 14:16, 8 months 6 days ago

Cardiol Therapeutics Receives FDA Orphan Drug Designation for CardiolRx

FDA Investment Orphan Drug Designation Cardiol Therapeutics Pericarditis
PRESS RELEASE

published on 02/27/2024 at 14:16, 8 months 6 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation on Cardiol Therapeutics Inc. FDA grants Orphan Drug Designation for CardiolRx in pericarditis treatment. Positive phase II study results expected in Q2 2024

FDA Cardiol Therapeutics Inc First Berlin Equity Research Orphan Drug Designation Pericarditis
PRESS RELEASE

published on 01/19/2024 at 12:41, 9 months 16 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided.

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Patient Recruitment Investment Potential

Accesswire

Published on 11/05/2024 at 03:30, 1 hour 50 minutes ago

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/05/2024 at 00:00, 5 hours 20 minutes ago

Axcap Ventures Announces Upsizing of Private Placement
Published on 11/04/2024 at 23:00, 6 hours 20 minutes ago

Jericho Energy Ventures Announces Plan to Separate Hydrogen Platform from Traditional Energy Assets to Maximize Shareholder Value
Published on 11/04/2024 at 23:00, 6 hours 20 minutes ago

APEX/IFSA Global EXPO Showcases the Future of Aviation With Nearly 3,000 Industry ‎Professionals in Attendance
Published on 11/04/2024 at 22:45, 6 hours 35 minutes ago

Alphinat Announces a Profit of $160,597 for Fiscal Year Ended August 31, 2023

View all ACCESSWIRE

EQS Group

Published on 11/04/2024 at 22:20, 7 hours ago

Adler Group S.A. announces the sale of its 62.78% stake in Brack Capital Properties N.V. to LEG Immobilien SE
Published on 11/04/2024 at 21:15, 8 hours 4 minutes ago

EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Published on 11/04/2024 at 19:00, 10 hours 19 minutes ago

EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Published on 11/04/2024 at 19:00, 10 hours 20 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Published on 11/04/2024 at 19:00, 10 hours 20 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 11/04/2024 at 18:13, 11 hours 7 minutes ago

Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 11 hours 7 minutes ago

Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 11 hours 8 minutes ago

Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Published on 11/04/2024 at 18:11, 11 hours 8 minutes ago

Déclaration mensuelle des actions et droits de vote – 31/10/2024
Published on 11/04/2024 at 17:45, 11 hours 35 minutes ago

Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.

View all LES ECHOS COMFI WIRE